Valuation: CorMedix Inc.

Market Cap 634M 550M 516M 470M 884M 60.55B 899M 6.07B 2.37B 30.31B 2.38B 2.33B 101B P/E 2026 *
16.9x
P/E 2027 * 814x
Enterprise Value 634M 550M 516M 470M 884M 60.55B 899M 6.07B 2.37B 30.31B 2.38B 2.33B 101B EV / Sales 2026 *
1.88x
EV / Sales 2027 * 2.21x
Free-Float
92.47%
Yield 2026 *
-
Yield 2027 * -
1 day+14.65%
1 week+8.39%
Current month+8.10%
1 month-2.16%
3 months+8.53%
6 months+10.90%
Current year-30.01%
1 week 7.1
Extreme 7.1
8.98
1 month 7.1
Extreme 7.1
8.98
Current year 6.12
Extreme 6.125
12.29
1 year 6.12
Extreme 6.125
14.96
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 10/05/2022
Director of Finance/CFO 54 29/08/2025
Compliance Officer 66 12/12/2023
Director TitleAgeSince
Director/Board Member 67 06/08/2015
Chairman 81 03/08/2017
Director/Board Member 70 16/08/2011
Date Insider Type Main position Quantity % Market Cap.
2/4/26 A Free

Chief Executive Officer

77,156 0.0979%
2/4/26 A Free

General Counsel

36,006 0.0457%
2/4/26 A Free

Chief Operating Officer

36,006 0.0457%
Change 5-day change 1-year change 3-year change Capi.($)
+14.65%+8.39%-32.62%+85.00% 634M
+1.98%+5.59%+63.89%+26.16% 334B
-1.36%-4.28%+23.93%-15.41% 69.97B
-1.10%+17.39%+54.57%+130.10% 11.43B
-1.26%+1.30%-1.92%-3.41% 8.58B
-0.68%+4.91%-12.57%-7.50% 4.84B
-0.72%+6.04%-27.25%+14.43% 4.34B
+1.29%+11.53%-0.90%+49.99% 4.27B
-1.50%+0.83%+10.58%+47.85% 2.74B
-0.28%+2.94%-5.19%-1.42% 2.23B
Average +1.39%+3.34%+7.25%+32.58% 44.35B
Weighted average by Cap. +1.31%+4.16%+52.90%+21.54%

Financials

2026 *2027 *
Net sales 337M 292M 274M 250M 470M 32.17B 477M 3.23B 1.26B 16.1B 1.27B 1.24B 53.72B 286M 248M 233M 212M 399M 27.34B 406M 2.74B 1.07B 13.69B 1.08B 1.05B 45.65B
Net income 45.16M 39.15M 36.7M 33.46M 62.96M 4.31B 63.97M 432M 169M 2.16B 170M 166M 7.2B 900K 780K 731K 667K 1.25M 85.9M 1.27M 8.61M 3.36M 43M 3.38M 3.31M 143M
Net Debt - -
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
13/08/26 $8.140 +14.65% 6,069,943
12/08/26 $7.100 -2.74% 1,353,419
11/08/26 $7.300 -3.05% 1,182,274
10/08/26 $7.530 +1.21% 842,650
07/08/26 $7.440 -0.93% 740,966
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.140USD
Average target price
15.40USD
Spread / Average Target
+89.19%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRMD Stock